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Abstract
Background
Compliance with WHO guidelines on HBV screening and treatment in HIV-coinfected
patients is often challenging in resource limited countries and has been poorly assessed in
sub-Saharan Africa.
Methods
Between 2015 and 2016, we assessed physician’s compliance with WHO guidelines on
HIV-HBV coinfection in the largest HIV clinic in The Gambia, and the hepatic outcomes in
HIV-HBV coinfected patients as compared to randomly selected HIV-monoinfected
controls.
Results
870 HIV-infected patients regularly seen in this clinic agreed to participate in our study. Only
187 (21.5%, 95% CI 18.8–24.3) had previously been screened for HBsAg, 23 (12.3%, 95%
CI 8.0–17.9) were positive of whom none had liver assessment and only 6 (26.1%) had
received Tenofovir. Our HBV testing intervention was accepted by all participants and found
94/870 (10.8%, 95% CI 8.8–13.1) positive, 78 of whom underwent full liver assessment
along with 40 HBsAg-negative controls. At the time of liver assessment, 61/78 (78.2%) HIV-
HBV coinfected patients received ART with 7 (11.5%) on Tenofovir and 54 (88.5%) on Lami-
vudine alone. HIV-HBV coinfected patients had higher APRI score compared to controls
(0.58 vs 0.42, p = 0.002). HBV DNA was detectable in 52/53 (98.1%) coinfected patients
with 14/53 (26.4%) having HBV DNA >20,000 IU/L. 10/12 (83.3%) had at least one
PLOS ONE | https://doi.org/10.1371/journal.pone.0179025 June 14, 2017 1 / 11
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Ndow G, Gore ML, Shimakawa Y, Suso P,
Jatta A, Tamba S, et al. (2017) Hepatitis B testing
and treatment in HIV patients in The Gambia—
Compliance with international guidelines and
clinical outcomes. PLoS ONE 12(6): e0179025.
https://doi.org/10.1371/journal.pone.0179025
Editor: Isabelle A Chemin, Centre de Recherche en
Cancerologie de Lyon, FRANCE
Received: March 22, 2017
Accepted: April 24, 2017
Published: June 14, 2017
Copyright: © 2017 Ndow et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: This work was supported by a Wellcome
Trust-Imperial College Institutional Strategic
Support Fund (ISSF) fellowship awarded to GN.
Additional funding was provided by the Wellcome
Trust-Imperial College Centre for Global Health
Research (GN), the NIHR Imperial Biomedical
Research Centre (MRT), and the EU 7th
Framework Programme (FP7-AFRICA-2010,
detectable 3TC-associated HBV resistance, which tended to be associated with increase in
liver fibrosis after adjusting for age and sex (p = 0.05).
Conclusions
Compliance with HBV testing and treatment guidelines is poor in this Gambian HIV
programme putting coinfected patients at risk of liver complications. However, the
excellent uptake of HBV screening and linkage to care in our study suggests feasible
improvements.
Introduction
Chronic hepatitis B virus (CHB) infection is a major public health problem and a leading
cause of morbidity and mortality globally. It affects approximately 250 million persons world-
wide [1] and accounts for 650,000 deaths annually [2]. Without effective interventions and
treatment, CHB infection will lead to an estimated 11.8 million deaths by 2030, primarily as a
result of cirrhosis and hepatocellular carcinoma (HCC) [3]. Most of these deaths will occur in
low-income countries (LICs) in sub-Saharan Africa (sSA) and Asia where CHB infection is
endemic.
The World Health Assembly (WHA), in response to the increasing CHB–related morbidity
and mortality, adopted a resolution to improve viral hepatitis prevention, testing and treat-
ment worldwide [4]. Subsequently, the United Nations General Assembly and the World
Health Organisation (WHO) respectively incorporated viral hepatitis elimination in the 2030
Agenda for Sustainable Development [5,6] and the WHO global health sector strategy on viral
hepatitis 2016–2021 [3,7]. The WHO further recommends hepatitis B surface antigen
(HBsAg) testing for all HIV-infected patients, and highly active antiretroviral therapy
(HAART) containing at least two drugs effective against hepatitis B virus (HBV) for all
HIV-HBV coinfected patients irrespective of disease stage or CD4 count [8], or where not fea-
sible to treat patients with severe liver disease [9].
Whilst both HIV and HBV are endemic in sSA, the prevalence of HIV-HBV coinfection is
highest in West Africa [10] where as many as 1 in 10 HIV-infected patients is coinfected with
HBV. Uncontrolled HIV-HBV coinfection, due either to lack of or ineffective antiretroviral
therapy (ART), increases the risk of death by more than twofold compared to HIV-monoin-
fected patients [11], irrespective of presence of liver disease [12]. Early and effective Tenofovir
Disoproxil Fumarate (TDF) based ART, on the other hand, reduces risk of death among coin-
fected patients [10,11] underlying the need for implementing universal HBV testing and
prompt ART treatment [8].
The Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) programme in 2016
found high HIV and HBV prevalence among Gambian communities (2% and 8.5% respec-
tively), with poor knowledge of hepatitis B and limited access to screening and treatment for
HBV infection [13]. One of Africa’s smallest and poorest nations, The Gambia has one of the
highest prevalence of HCC in West Africa [14] with two-thirds of these cases attributable to
HBV infection [15]. In order to comply with the recent WHO goal for HBV elimination, we
assessed the coverage of hepatitis B testing and treatment, and its impact on clinical outcomes
in the largest HIV treatment centre in The Gambia, West Africa.
HBV testing and treatment in HIV patients
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Materials and methods
Patients and study design
This cross-sectional study enrolled HIV infected patients aged18years (range 22–63 years)
registered at the Hands on Care HIV clinic in Brikama (The Gambia) who have had at least
two successful clinic visits and baseline investigations. After written consent, we reviewed
patient case notes to determine the coverage of hepatitis B surface antigen (HBsAg) testing for
all HIV patients and use of TDF-based ART for known HIV-HBV coinfected patients. There-
after, we screened the patients for HBsAg using the Determine1 rapid point-of-care kit
(Alere1, USA). All HBsAg positive patients (HIV-HBV coinfected) and randomly selected
HBsAg negative controls (HIV-monoinfected) had confirmatory HBsAg serology test (Archi-
tect HBsAg, Abbott, USA) and were further invited for complete liver assessment. Demo-
graphic and clinical information such as age, gender, past medical history, duration of HIV
infection and antiretroviral drug exposure were collected, and a clinical examination and bed-
side ultrasonography performed. Liver transaminases (Vitros 350 Analyzer, Ortho Clinical
Diagnostics, USA), haemoglobin and platelet count (CELL-DYN 3700 sample loader, Abbott,
USA), HIV RNA (Abbott Real Time HIV-1 assay, 40copies/mL limit of detection), CD4+ T-
cell count (flow cytometry) and in-house HBV DNA viral load quantification [16] were mea-
sured for all patients.
Assessment of liver fibrosis
In accordance with WHO guidelines for setting without access a transient elastography device
(Fibroscan), we assessed liver fibrosis using biochemical markers—aspartate aminotransferase
(AST)-to-platelet ratio index (APRI) and FIB-4. APRI was calculated as [AST level (IU/L) /
upper limit of normal for AST (IU/L) × 100/platelet count (109/L)], and FIB-4 as [age (years) x
AST (IU/L) / (platelet count (109/L) x ALT (IU/L)1/2)]. Significant fibrosis defined was defined
as APRI>1.5 [17] or FIB-4 >3.25 [18].
HBV molecular analysis and polymerase gene sequencing
DNA was extracted from 500μL plasma using the QIAamp DNA Blood MiniKit (QIAgen,
Germany). HBV DNA was quantified was by TaqMan based quantitative PCR assay with
lower limit of detection of 50IU/L [16], using probe (200nM) sequence HBVTAQPR:5'-
FAM-CCTCTKCATCCTGCTGCTATGCCTCATC-3’MGBNFQwith forward and reverse primer
(400nM) sequences HBVTAQ1:5'-GTGTCTGCGGCGTTTTATCA-3' and HBVTAQ2:5'-
GACAAACGGGCAACATACCTT-3’ respectively [19]. Hepatitis B polymerase gene sequence
was assessed in all participants with HBV DNA viral load20,000IU/L.
The region from nucleotide 101 to 1149 of the HBV polymerase (pol) gene containing the
highly conserved tyrosine-methionine-aspartate-aspartate (YMDD) motif was amplified by
standard PCR using high fidelity polymerases (Supermix High Fidelity polymerase from Invi-
trogen or Q51 High-Fidelity DNA Polymerase from New England BioLabs) and primers sense
5’-AYTGTCTCTTCCAYMTCRTC-3’ and antisense 5’-GGGGTAAAGGTTCAGRTAYTG-3’.
Genotype of the amplified sequence was assessed using the NCBI genotyping tool [20].
Statistical analyses
Demographic, clinical and virological characteristics of the study participants were presented
according to their HBsAg status, and comparison made between HIV-monoinfected and
HIV-HBV coinfected patients using the chi-squared test, Fisher’s exact test, or Wilcoxon rank-
sum test. Factors associated with significant fibrosis (APRI >1.5) were identified using
HBV testing and treatment in HIV patients
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univariable logistic regression. As the number of participants with APRI>1.5 was small, mul-
tivariable analysis was not performed.
Ethical approval
The MRC Scientific Coordinating committee and the joint Gambia Government/MRC Ethics
committee approved this study (SCC1388). Consenting of participants followed group and
individual sensitization, explanation of a study protocol and sufficient time for questions and
discussion with spouse/family.
Results
Study population and compliance with guidelines
Between September 2015 and February 2016, 870 HIV-infected patients regularly seen at the
Hands on Care HIV clinic were invited to participate in our study and all agreed to take part.
The review of patient case notes revealed that only 187 (21.5%, 95% CI 18.8–24.3) had previ-
ously been tested for HBsAg, with 23 (12.3%, 95% CI 8.0–17.9) found to be HIV-HBV coin-
fected. None had a liver assessment based on liver transaminases, ultrasound, measurement of
liver fibrosis or liver biopsy. Whilst all 23 patients previously known to be coinfected had been
receiving ART, only 6 (26.1%, 95 CI 10.2–48.4) had received a TDF-based regimen.
Of 870 patients accepted for the HBsAg screening, 94 tested positive giving a seroprevalence
of 10.8% (95% CI 8.8–13.1). Of these, 15 (16%) were lost to follow up, and 1 died before the
liver assessment. The remaining 78 HIV-HBV coinfected patients underwent full liver assess-
ment, along with 40 randomly selected HBsAg negative controls (Fig 1).
Of the 78 coinfected patients who completed liver assessment as part of our study, 61
(78.2%, 95% CI 67.4–86.1) received ART, with 54/61 (88.5%, 95% CI 77.4–94.5) receiving
Lamivudine (3TC) without TDF and only 7/61 (11.5%) receiving a TDF-based regimen.
Median transaminase was within normal limits with only 5 patients (6.4%) having ALT above
the upper limit of normal (ULN) and 1 (1.3%) with ALT>2xULN. Table 1 provides the char-
acteristics of the study population by HBsAg status.
Assessment of liver fibrosis
Compared to HIV-monoinfected patients, HIV-HBV coinfected patients had significantly
higher median APRI (0.42 vs 0.58, p = 0.002) and FIB-4 (1.72 vs 1.35, p = 0.004), suggesting
higher rate of liver fibrosis in coinfected patients. Table 2 shows the factors associated with sig-
nificant liver fibrosis.
HBV molecular virology in 3TC exposed patients
Of 54 coinfected patients who were treated with 3TC without TDF, after a median duration of
28 months (IQR 12–60) on 3TC, HBV DNA and HIV RNA were detectable in 52/53 (98.1%,
95% CI 87.1–99.8) and 15/38 (39.5%, 95% CI 24.8–56.3) respectively. 14 of 53 (26.4%, 95% CI
16.0–40.3) had HBV DNA>20,000 IU/L. We successfully sequenced the region of the poly-
merase gene containing the YMDD motif in 12 of these 14 patients. 10 (83.3%) had M204V/I
mutations present, with 8 (66.7%) having additional compensatory mutations at rtL180M and
3 (25.0%) at both rtL180M and rtV173L. Phylogenetic analysis of the polymerase gene
sequence showed all but one patient (HBV genotype A) were infected with HBV genotype E.
We assessed the joint effect of HBV co-infection and 3TC resistance mutations on signifi-
cant fibrosis (APRI>1.5) in HIV-infected patients. Compared to mono-infected, the preva-
lence of significant fibrosis was higher in those coinfected, and especially in those with 3TC
HBV testing and treatment in HIV patients
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resistance mutations. While no HIV-monoinfected patients (0/39) had significant fibrosis, 6/
66 (9%) of patients coinfected with wild type HBV and 1/8 (13%) coinfected with resistant
HBV strain had significant fibrosis (p for trend 0.05).
Discussion
In The Gambia, a West African country highly endemic for HBV infection [13], our study pro-
vides two key messages: 1) poor compliance with the WHO hepatitis B testing and treatment
guidelines [9] is poor with only 21.5% of HIV patients systematically screened for HBV infec-
tion and less than 15% on TDF-based ART, which puts HIV patients at risk of liver complica-
tions; 2) testing and linkage to care for HBV infection in HIV patients is accepted and feasible
in HIV care programme in The Gambia.
To date, the compliance with the WHO guidelines [8,9] on the management of HBV and
HIV coinfection in sSA—a region with high HIV-HBV coinfection prevalence [10], has been
poorly documented. We found that in 2016, despite strong international recommendations
Fig 1. Flow diagram of the study population.
https://doi.org/10.1371/journal.pone.0179025.g001
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and increasing global commitment to HBV elimination, HBsAg testing and effective HBV
treatment remains poor in the largest Gambian HIV facility predisposing coinfected patients
to severe clinical and virological outcomes, increased risk of liver-related morbidity, and
diminished benefits of ART.
Table 1. Characteristics of the study population by HBV coinfection.
Parameters HIV-HBV (n = 78) HIV (n = 40) P value
Median age (years, IQR) 38 (35–48) 42 (35–46) 0.5
Male sex (n, %) 8 (20) 16 (21) 0.9
Median BMI (Kg/m2, IQR) 21 (19–24) 22 (20–25) 0.4
HIV infection type (n, %)
HIV1
HIV2
HIV1+2
58 (78)
3 (4)
13 (18)
34 (90)
2 (5)
2 (5)
0.2
Median duration since HIV diagnosis (months, IQR) 34 (14–68) 66 (20–82) 0.04
CD4+ T-cell count (n, %)
<200 cells/mm3
200 cells/mm3
24 (34)
46 (66)
13 (34)
25 (66)
1.0
Median CD4+ T-cell count (cells/mm3, IQR) 293.5 (147–444) 302 (170–411) 0.7
HIV RNA (n, %)
Undetectable
Detectable
30 (53)
27 (47)
26 (70)
11 (30)
0.09
Median HIV RNA (log copies/mL, IQR) 4.1 (3.2–5.0) 4.2 (3.2–4.6) 0.7
HBV DNA (n, %)
Undetectable
50–2,000 IU/mL
2,000–20,000 IU/mL
2, 000 IU/mL
1 (1)
46 (60)
12 (16)
18 (23)
NA NA
Median ALT (IU/L, IQR) 15 (12–25) 17 (11–26) 0.9
Median AST (IU/L, IQR) 28 (24–40) 24 (19–30) 0.004
Median platelet count (x109/L, IQR) 186 (152–220) 198 (163–238) 0.1
APRI (n, %)
<0.5
0.5–1.5
1.5
29 (39)
38 (51)
7 (10)
27 (69)
12 (31)
0
0.005
Median APRI (IQR) 0.58 (0.43–0.88) 0.42 (0.35–0.53) 0.002
FIB-4 (n, %)
<1.45
1.45–3.25
3.25
30 (40)
39 (53)
5 (7)
25 (64)
14 (36)
0
0.03
Median FIB-4 (IQR) 1.72 (1.22–2.34) 1.35 (1.06–1.63) 0.004
ART regimen (n, %)
Never treated
3TC without TDF
TDF
17 (22)
54 (69)
7 (9)
5 (13)
29 (74)
5 (13)
0.5
Duration of 3TC exposure (n, %)*, **
<12 months
12–60 months
60 months
14 (23)
32 (52)
15 (25)
7 (21)
13 (38)
14 (41)
0.2
*This analysis only includes those who have ever received ART;
**3TC without a second HBV active anti-viral drug
ALT—alanine aminotransferase; APRI—AST to platelet ratio index; ART—antiretroviral therapy; AST—
aspartate aminotransferase; BMI—body mass index; HIV—Human Immunodeficiency virus; RNA—
ribonucleic acid; TDF—Tenofovir Disoproxil Fumarate; 3TC—Lamivudine
https://doi.org/10.1371/journal.pone.0179025.t001
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In our study, none of the 870 HIV-infected patients refused to be screened for HBV and
almost 85% of HBsAg positive participants accepted to undergo liver assessment. This result is
important since it suggests that HBV screening and linkage to care for HBV infection may be
widely accepted in HIV-infected patients and feasible in HIV care facilities in sSA. This needs
to be confirmed on a larger scale.
Whilst some countries in sSA successfully adopted a TDF-based first-line ART regimen in
HIV reference centres [21], indication to treat and choice of ART regimen in Gambian HIV
clinics was primarily determined by the type and stage of HIV infection. As a result, 3TC, a
cheap and well-tolerated nucleoside analogue has been the backbone of first line ART in The
Gambia since its introduction over a decade ago [22]. Although 3TC is an effective antiviral
drug, it is associated with an increased risk of HBV resistance mutations following 12 to 24
months of monotherapy in patients with HBV infection [23]. Unsurprisingly, HBV DNA was
detectable in almost all our study patients (98.1%) who received prolonged 3TC without TDF.
We found significantly higher prevalence (83.3%) of 3TC associated HBV resistance muta-
tions compared to the 14.2% reported in a similar Gambian HIV-HBV cohort six year earlier
who received 3TC without a second anti-HBV drug [24], as well as the 29.3% and 8.7%
reported in a Ghanaian [25] and Ivorian [26] coinfected patients respectively. Our findings
confirm that widespread prolonged usage of 3TC monotherapy in ART poses diagnostic and
management problems to individual patients as well as a potential public health risk.
Table 2. Factors associated with significant liver fibrosis (APRI1.5) in HIV-infected participants
(n = 113).
Prevalence of significant fibrosis (%) Crude odds ratios
OR, 95% CI P value
Age group
<40
40
5/58 (9)
2/55 (4)
1.0
0.4 (0.1–2.2)
0.3
Sex
Women
Men
6/90 (7)
1/23 (4)
1.0
0.6 (0.1–5.6)
0.7
BMI
<25
25
7/86 (8)
0/27 (0)
1.0
NA
0.1
Steatosis
No
Yes
6/105 (6)
1/8 (13)
1.0
2.4 (0.2–22.4)
0.5
HIV infection type
HIV1
HIV2
HIV1+2
3/89 (3)
0/4 (0)
3/15 (20)
1.0
NA
7.2 (1.3–39.6)
0.02
HIV RNA
Undetectable
Detectable
0/53 (0)
6/37 (16)
NA
0.002
CD4+ T-cell count
<200 cells/mm3
200 cells/mm3
1/36 (3)
5/68 (7)
1.0
2.8 (0.3–24.7)
0.4
HBV co-infection
No
Yes
0/39 (0)
7/74 (10)
NA
0.04
ART
Never
3TC without TDF
TDF
2/19 (11)
5/82 (6)
0/11 (0)
1.0
0.6 (0.1–3.1)
NA
0.5
https://doi.org/10.1371/journal.pone.0179025.t002
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The high proportion of patients with detectable HIV viral load and low CD4 count after
many months of ART, as well as the detectable HBV DNA among almost all coinfected
patients receiving TDF in our study could be the result of unsatisfactory adherence to therapy,
which might contribute to higher levels of HBV viremia and consequently to higher fibrosis
and HBV resistance. Another explanation could be the deteriorating HIV services in The
Gambia since 2007 when its former president claimed to have found herbal cure for HIV infec-
tion. This claim disrupted decades of HIV campaign and negatively impacted vital HIV ser-
vices and research partnerships resulting in significant reduction in competent personnel and
services in HIV facilities and suboptimal HIV care with frequent medication stock outs and
several patients having their ARV regimens switched often. These underline the urgent need
to improve HIV services and drug provision in Gambian HIV facilities.
HBV co-infection increases liver fibrosis [25, 27–31] as well as both all cause and liver
related mortality [11,32], often in the absence of any evidence of liver disease [12]. Although
our study lacked statistical power to show definitively a positive relationship between 3TC
resistance mutation and increase in liver fibrosis, we show a trend towards such relationship
(p = 0.05). Prompt initiation of TDF-based ART has been shown to reduce HBV viral replica-
tion and mortality in European [33] and Africa HIV-HBV cohort [11,12], further strengthen-
ing the need for compliance with the WHO HBV testing and treatment guidelines in Africa. It
is worth noting that the uptake of TDF in first-line ART regimens in sSA is poorly docu-
mented. Our study shows that until 2016, only a minority of HIV patients in The Gambia
received HBV testing and an even lesser proportion (7/78) of HIV-HBV coinfected patients
received TDF. None of the patients had benefitted from a liver assessment even on the basis of
liver transaminases. Indeed the local laboratory at this HIV facility, and almost all other HIV
facilities in The Gambia, do not have the capacity to assess liver biochemistry. The 2016 con-
solidated HIV guidelines [8] recommending TDF-based ART for all HIV patients irrespective
of degree of liver disease are thus well adapted to resource limited African settings, and African
HIV facilities need to be supported to implement these guidelines.
Our study has a few limitations: first, we analysed a limited number of HIV-HBV coinfected
patients; second, we assessed liver fibrosis using APRI score as recommended by the WHO for
resource-limited settings without access to Fibroscan, which is the case for most HIV facilities
in Africa where Fibroscan is rarely available outside research settings. The reliability and use-
fulness of platelet-based biomarkers like APRI for assessing liver fibrosis in HIV patients in
Africa has been questioned [34] mainly because thrombocytopenia is commonly associated
with advanced HIV infection. Third, our study did not assess for hepatitis C virus (HCV) and
hepatitis D virus (HDV) coinfection. However, previous studies in The Gambia confirmed
very low prevalence rates of both HCV and HDV infections [13]. Finally, our study suggests
that adherence to ART was not satisfactory but we did not directly assess adherence to ART.
Conclusion
Compliance with international HBV testing and treatment guidelines for HIV-infected
patients is poor in this Gambian HIV programme, resulting in a low coverage of HBV testing,
prolonged treatment with 3TC without TDF for coinfected patients, and poor HBV viral sup-
pression with increased risk of HBV resistance and liver complication. However, interventions
to improve HBV screening and linkage to care for HBV infection in HIV facilities are feasible.
Supporting information
S1 File. Data underlying the findings described in the manuscript.
(XLSX)
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